These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6687319)

  • 21. Effect of gemfibrozil on serum lipid levels.
    Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C
    Artery; 1980; 7(3):224-31. PubMed ID: 7008748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
    Micheli H; Pometta D; Gustafson A
    Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V; Klör HU; Wechsler JG; Ditschuneit H
    J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
    Muacević-Kataneca D; Bradamante V; Reinec Z; Sucić M; Poljicanin T; Busljeta I; Metelko Z
    Arzneimittelforschung; 2005; 55(5):271-5. PubMed ID: 15960426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fatty acid metabolism in primary hyperlipoproteinemia (HLP) (author's transl)].
    Reuter W
    Dtsch Z Verdau Stoffwechselkr; 1979; 39(3):124-9. PubMed ID: 520271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
    Pons P; Rodríguez M; Robaina C; Illnait J; Más R; Fernández L; Fernández JC
    Int J Clin Pharmacol Res; 1994; 14(1):27-33. PubMed ID: 7927958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of plant sterols in combination with other cholesterol-lowering foods.
    Jenkins DJ; Kendall CW; Nguyen TH; Marchie A; Faulkner DA; Ireland C; Josse AR; Vidgen E; Trautwein EA; Lapsley KG; Holmes C; Josse RG; Leiter LA; Connelly PW; Singer W
    Metabolism; 2008 Jan; 57(1):130-9. PubMed ID: 18078870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy.
    Hedman M; Miettinen TA; Gylling H; Ketomäki A; Antikainen M
    J Pediatr; 2006 Feb; 148(2):241-6. PubMed ID: 16492436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Removal of intravenous Intralipid in patients with familial hypercholesterolemia during inhibition of cholesterol absorption and synthesis.
    Ketomäki A; Gylling H; Miettinen TA
    Clin Chim Acta; 2004 Jun; 344(1-2):83-93. PubMed ID: 15149875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias].
    Goranov I; Naumova R; Kerekovska M; Balabanski L
    Vutr Boles; 1987; 26(1):96-101. PubMed ID: 3590738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serum cholesterol and triglyceride levels in patients with type II hyperlipoproteinemia treated with probucol].
    Markiewicz M; Rymar B; Horubała-Bielak G; Koziara Z
    Wiad Lek; 1984 Oct; 37(19):1489-93. PubMed ID: 6528586
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapy of hyperlipoproteinemia type IIa and IIb with etiroxate-HCl. Dose-response comparison].
    Banz H; Gall FP
    Fortschr Med; 1979 Nov; 97(42):1942-1947. PubMed ID: 520990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soybean protein diets in the management of type II hyperlipoproteinaemia.
    Verrillo A; de Teresa A; Carandente Giarrusso P; La Rocca S
    Atherosclerosis; 1985 Mar; 54(3):321-31. PubMed ID: 4039593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Application of Friedewald's LDL-c-estimation formula to heterozygotes of familial hypercholesterolemia].
    Nakajima K; Hata Y
    Rinsho Byori; 1986 Oct; 34(10):1163-7. PubMed ID: 3807002
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effect of bezamidine on plasma cholesterol and triglyceride levels in patients with familial hyperlipoproteinemia].
    Kukharchuk VV; Koshechkin VA; Konovalov GA; Rozhkova TA; Solov'eva EIu
    Kardiologiia; 1990 Dec; 30(12):16-8. PubMed ID: 2097388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The use of sorbinicate in the treatment of hyperlipoproteinemia type IIa and IIb].
    Guida L; Grimaldi S; Avella F; Marullo L; Mascio G
    Farmaco Prat; 1981 Jan; 36(1):13-22. PubMed ID: 7227491
    [No Abstract]   [Full Text] [Related]  

  • 40. Application of soluble dietary fibres in treatment of hyperlipoproteinemias.
    Grudeva-Popova J; Krachanova M; Djurdjev A; Krachanov C
    Folia Med (Plovdiv); 1997; 39(1):39-43. PubMed ID: 9141790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.